Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Share:
Related TEVA
Earnings Scheduled For July 30, 2015
Eagle Pharma Targets Hiked At Piper Jaffray On 'Room For Value Creation'
IBD 50: 10 Top Stocks Reporting Earnings This Week (Investor's Business Daily)
Related NVS
Must Watch Stocks for June 29, 2015
The Note Moving Pharma Giants Today
Theravance: On Track To Deliver Rising Dividends (Seeking Alpha)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA

 

Related Articles (TEVA + NVS)

Get Benzinga's Newsletters